Condition: Nasopharyngeal Cancinoma (NPC) · Sponsor: Sun Yat-sen University
This phase II randomized trial compares the efficacy and safety of Toripalimab combined with three different platinum-based induction chemotherapy regimens, sequentially followed by standard concurrent chemoradiotherapy, for the treatment of locally advanced nasopharyngeal carcinoma (NPC). The study is aimed to pick up the most effective platinum-based induction chemotherapy regimen plus Toripalimab for these patients which provides the most survival benefit.
This description comes directly from the study's public registry record.
Hai-Qiang Mai, Dr. · +8602087343380 · maihq@sysucc.org.cn
Li-Ting Liu, Dr. · +8602087343380 · liult@sysucc.org.cn
Always discuss trial participation with your own doctor first.
| Dongguan People's Hospital | Dongguan, Guangdong, China | Recruiting |
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong, China | Recruiting |
| Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen | Shenzhen, Guangdong, China | Recruiting |
| Affiliated Hospital of Guangdong Medical University | Zhanjiang, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07362979